Meeting Banner
Abstract #1515

One Year Followup Evaluation of Hepatic Triglycerides in Colorectal Cancer Patients Treated with Adjuvant Chemotherapy Using 1H Magnetic Resonance Spectroscopy

Kristen Zakian1, Jing Qi2, Yuman Fong3, Leonard Saltz4, Michael D'Angelica3, Nancy Kemeny4, Mithat Gonen5, Jinru Shia6, Amita Shukla-Dave1, Kinh Gian Do7, William Jarnagin3, Lawrence Schwartz2, Jason A. Koutcher1

1Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 2Columbia University College of Physicians and Surgeons, New York, NY, United States; 3Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 4Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 5Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 6Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 7Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States


To evaluate hepatic triglyceride changes during and after adjuvant chemotherapy in colorectal cancer patients, 1H MRS was performed prior to chemotherapy, after 6 months of treatment and at 1 year follow up. Nine FOLFOX-treated patients and 7 patients treated with hepatic arterial infusion of FUDR and systemic irinotecan (HAI-FUDR/IRI completed this 1 year study. FOLFOX patients who experienced an increase in fat to fat+water ratio (FFW) during treatment tended to return toward baseline after 6 months off-treatment unless they experienced a significant weight-gain. HAI-FUDR patients did not show a trend toward increasing hepatic lipids while on treatment.